Ilko Menkov Portfolio
Invests via Vestal Point Capita LLP | Managed by Ryan Wilder
Invests via Vestal Point Capita LLP
Managed by Ryan Wilder
Automatically Tracked
Ilko Menkov Profile
With a robust background in strategic investments and financial management, Ilko Menkov is an influential figure within the European private equity landscape. His expertise encompasses extensive operational leadership, particularly in technology and innovation sectors, where he has played a pivotal role in scaling startups and driving sustainable growth. Leveraging deep market insights, he collaborates closely with entrepreneurs to enhance business models that foster resilience and expansion. This focus on value creation has established him as a respected investor-operator who continuously seeks transformative opportunities across various markets.
With a robust background in strategic investments and financial management, Ilko Menkov is an influential figure within the European private equity landscape. His expertise encompasses extensive operational leadership, particularly in technology and innovation sectors, where he has played a pivotal role in scaling startups and driving sustainable growth. Leveraging deep market insights, he collaborates closely with entrepreneurs to enhance business models that foster resilience and expansion. This focus on value creation has established him as a respected investor-operator who continuously seeks transformative opportunities across various markets.
Investment Philosophy & Strategy
Grounded in an extensive history of entrepreneurial ventures, Ilko Menkov applies a unique blend of operational insights and strategic foresight to his investment endeavors. His approach is primarily driven by identifying disruptive trends within technology sectors, enabling him to cultivate promising startups poised for exponential growth. By prioritizing partnerships with visionary founders, he aligns resources and expertise to optimize scalability and impact. This emphasis on transformative potential allows him to capitalize on market dynamics while fostering innovation that drives competitive advantage.
Grounded in an extensive history of entrepreneurial ventures, Ilko Menkov applies a unique blend of operational insights and strategic foresight to his investment endeavors. His approach is primarily driven by identifying disruptive trends within technology sectors, enabling him to cultivate promising startups poised for exponential growth. By prioritizing partnerships with visionary founders, he aligns resources and expertise to optimize scalability and impact. This emphasis on transformative potential allows him to capitalize on market dynamics while fostering innovation that drives competitive advantage.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
121.12%
Gain -0.31%
Monthly
2.58%
Yearly
35.87%
Drawdown
33.02%
$4.25B
Equity
Holdings
$4.25B
Investment
$3.32B
$1.66B
Profit -$7.93M
Realized
$728.19M
Unrealized
$931.77M
Dividends
$9.92M
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-0.31%
Profit
-$7.93M
Win %
62%
This Week
Compared To Last Week
Gain
-0.19%
Profit
-$7.91M
Win %
62%
This Month
Compared to last month
Gain
-0.19%
Profit
-$7.91M
Win %
62%
This Year
Compared to last year
Gain
18.85%
Profit
$674.34M
Win %
63%
SRZN Surrozen, Inc.
+6.62%
+$467,283.18 
QURE uniQure N.V.
+3.41%
+$516,954.24 
REGN Regeneron Pharmaceuticals, Inc.
+3.29%
+$971,598.8 
BCAX Bicara Therapeutics Inc.
+3.16%
+$4.5M 
ABSI Absci Corporation
+1.83%
+$32,510.66 
ENGN enGene Therapeutics Inc.
+1.71%
+$64,950 
ELVN Enliven Therapeutics, Inc.
+1.59%
+$2.79M 
BSX Boston Scientific Corporation
+1.59%
+$584,000 
CADL Candel Therapeutics Inc.
+1.42%
+$157,500 
BMY Bristol-Myers Squibb Company
+0.69%
+$450,000 
ABVX Abivax SA ADR
+0.47%
+$885,000 
SNY Sanofi American Depositary Receipt
+0.44%
+$266,002.8 
WST West Pharmaceutical Services, Inc.
+0.4%
+$102,749.25 
INSP Inspire Medical Systems, Inc.
+0.38%
+$102,461.11 
KALV KalVista Pharmaceuticals Inc.
0%
$0 
NUVL Nuvalent, Inc.
0%
$0 
SLNO Soleno Therapeutics, Inc.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
MYGN Myriad Genetics Inc.
-46.74%
-$4.14M 
GLUE Monte Rosa Therapeutics, Inc.
-27.16%
-$22.2M 
VCYT Veracyte Inc.
-22.52%
-$1.76M 
BBNX Beta Bionics Inc.
-10.09%
-$3.18M 
NBIX Neurocrine Biosciences Inc.
-10.08%
-$23.38M 
TENX Tenax Therapeutics Inc.
-9.27%
-$74,814.6 
AGIO Agios Pharmaceuticals Inc.
-8.34%
-$1.23M 
MPLT MapLight Therapeutics, Inc.
-7.2%
-$424,200 
URGN Urogen Pharma Ltd.
-6.94%
-$396,375.15 
COGT Cogent Biosciences, Inc.
-5.87%
-$2.99M 
IMTX Immatics N.V.
-5.87%
-$3.33M 
WGS GeneDx Holdings Corp.
-5.58%
-$962,500 
MNPR Monopar Therapeutics Inc.
-5.5%
-$412,787.58 
DNLI Denali Therapeutics Inc.
-5.46%
-$2.36M 
ANRO Alto Neuroscience Inc.
-5.45%
-$3.22M 
MDGL Madrigal Pharmaceuticals, Inc.
-5.23%
-$811,559.09 
SLDB Solid Biosciences Inc.
-5.07%
-$2.15M 
LXEO Lexeo Therapeutics Inc.
-5.06%
-$984,500 
AVR Anteris Technologies Ltd.
-4.85%
-$457,912 
OKUR OnKure Therapeutics Inc.
-4.5%
-$331,167.42 
RGNX Regenxbio Inc.
-4.25%
-$46,665.75 
RAPP Rapport Therapeutics Inc.
-4.21%
-$2.59M 
VKTX Viking Therapeutics Inc.
-4.14%
-$1.25M 
CYTK Cytokinetics, Incorporated
-4.09%
-$987,000 
FULC Fulcrum Therapeutics Inc.
-3.76%
-$154,000 
GERN Geron Corporation
-3.73%
-$127,000 
CBIO Crescent Biopharma, Inc.
-3.66%
-$825,000 
TYRA Tyra Biosciences, Inc.
-3.57%
-$63,720.05 
SRRK Scholar Rock Holding Corporation
-3.46%
-$2.24M 
ARVN Arvinas Inc.
-3.25%
-$244,475.55 
VYGR Voyager Therapeutics Inc.
-3.19%
-$300,293.6 
OLMA Olema Pharmaceuticals Inc.
-3.13%
-$158,563.87 
PALI Palisade Bio Inc.
-3.06%
-$150,000 
ARWR Arrowhead Pharmaceuticals Inc.
-3.06%
-$6.07M 
VERA Vera Therapeutics Inc.
-2.87%
-$1.3M 
ASND Ascendis Pharma A/S
-2.85%
-$2.69M 
BCRX BioCryst Pharmaceuticals Inc.
-2.81%
-$1.83M 
IRON Disc Medicine Inc.
-2.79%
-$1.55M 
GEHC GE HealthCare Technologies Inc.
-2.75%
-$480,000.75 
ZBIO Zenas BioPharma, Inc.
-2.57%
-$166,000 
NVCR NovoCure Ltd.
-2.56%
-$97,500 
RVMD Revolution Medicines Inc.
-2.42%
-$11.02M 
MGNX Macrogenics Inc.
-2.38%
-$25,200 
XENE Xenon Pharmaceuticals Inc.
-2.37%
-$972,648 
APRE Clear Creek Independent School District
-2.36%
-$5,250 
DYN Dyne Therapeutics Inc.
-2.14%
-$2.2M 
ZURA Zura Bio Ltd.
-1.99%
-$56,210 
DRUG Bright Minds Biosciences Inc.
-1.84%
-$674,477.03 
GMED Globus Medical Inc.
-1.83%
-$897,464.4 
RGEN Repligen Corporation
-1.8%
-$2.4M 
TECX Tectonic Therapeutic Inc.
-1.68%
-$157,439.67 
NRIX Nurix Therapeutics Inc.
-1.57%
-$2.4M 
UTHR United Therapeutics Corporation
-1.54%
-$608,249.25 
SVRA Savara Inc.
-1.44%
-$208,004.16 
PTGX Protagonist Therapeutics Inc.
-1.44%
-$652,318 
CLDX Celldex Therapeutics Inc.
-1.12%
-$526,389.73 
NKTR Nektar Therapeutics Inc.
-1.09%
-$222,300 
ZBH Zimmer Biomet Holdings, Inc.
-1.08%
-$195,700 
AZN AstraZeneca PLC American Depositary Shares
-0.99%
-$170,000 
ALC Alcon Inc.
-0.96%
-$536,000 
BMRN Biomarin Pharmaceutical Inc.
-0.92%
-$2M 
TARS Tarsus Pharmaceuticals Inc.
-0.84%
-$99,999.8 
SGP SpyGlass Pharma, Inc.
-0.84%
-$126,684.4 
TRVI Trevi Therapeutics Inc.
-0.81%
-$324,975.6 
WAT Waters Corporation
-0.79%
-$298,999 
DMRA Damora Therapeutics, Inc.
-0.75%
-$132,000 
NYXH Nyxoah SA
-0.71%
-$8,686.61 
PASG Passage Bio Inc.
-0.45%
-$6,100 
TSHA Taysha Gene Therapies Inc.
-0.26%
-$270,000 
PODD Insulet Corporation
-0.2%
-$16,697.32 
IMCR Immunocore Holdings plc American Depositary Receipt
-0.18%
-$166,012.08 
APGE Apogee Therapeutics Inc.
-0.16%
-$231,004.4 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 625 | Longs Won 333/625 53% | Profit Factor 3.97 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $11.68M |
| Average Win $6.66M | Best Trade (Aug 02) $187.78M | Sharpe Ratio -22.73 |
| Average Loss -$1.92M | Worst Trade (Sep 30) -$22.73M | Z-Score -1.66 (91.32%) |
| Commissions $0 | Avg. Trade Length 8m 1d | Expectancy $2.66M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 2,217 | 1,996 | 1,774 | 1,552 | 1,330 | 1,109 | 887 | 665 | 443 | 222 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Ilko Menkov?
The largest contributions to the portfolio's profits come from the following stocks: uniQure N.V - $212.08M, Tyra Biosciences, Inc - $65.34M, Dianthus Therapeutics Inc - $62.67M, Jazz Pharmaceuticals plc - $50.57M, and Terns Pharmaceuticals, Inc - $43.12M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Structure Therapeutics Inc - $28.23M, Geron Corporation - $24.35M, Alx Oncology Holdings Inc - $19.55M, Cytokinetics, Incorporated - $15.83M, and Astria Therapeutics Inc - $13.83M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Ilko Menkov's portfolio generate?
The portfolio generates substantial dividend income, with a total of $9.92M earned over time. The largest contributors to dividend income include Sanofi American Depositary Receipt - $3.39M, Bristol-Myers Squibb Company - $1.87M, Merck & Co., Inc - $1.61M, Abbott Laboratories - $628,750, and GSK plc Sponsored ADR - $568,898.75. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Ilko Menkov's monthly returns?
Ilko Menkov's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Ilko Menkov's strategy be considered aggressive or moderate?
Ilko Menkov's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Ilko Menkov's strategy?
Ilko Menkov's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
